Pharmacology of Infectious Disease: Essential Elements for an Impactful Clinical Pharmacy Practice – Eric Wombwell

Salepage link: At HERE. Archive:

Dr. Eric Wombwell, PharmD, and Board Certified Infectious Disease Pharmacist will be your guide in this seminar, as you learn the latest evidence in the pharmacology of infectious diseases and application of this evidence to enhance your clinical pharmacy practice. 

With new antibiotics, vaccines, treatment guidelines, and evidence-based research continuously becoming available, the need to stay up-to-date is an imperative for pharmacists. The CDC recommends that pharmacists receive ongoing education about a variety of areas, including adverse reactions to antibiotics, antibiotic resistance and optimal prescribing.

Dr. Wombwell will draw attention to clinical situations where antibiotics are overprescribed, unnecessarily used, and underutilized in the treatment of infections. He will provide approaches to improve antibiotic use in these situations—resulting in reduced antibiotic cost, resistance, and collateral damage, improving patient outcomes in both outpatient and inpatient environments.

You’ll leave with the knowledge and strategies to:

• Integrate current, best-practice treatment guidelines
• Limit adverse reactions from antibiotics
• Implement antimicrobial de-escalation strategies
• And more!

Purchase this seminar, and as an added bonus, you’ll receive FREE access to the seminar Pharmacology of Pain Management for End-of-Life Care: Recommendations for Advanced Clinical Pharmacy Practice to build your knowledge about the pharmacology surrounding pain and comfort.

The need for robust antibiotic stewardship has never been more pressing. Purchase today!

1. Develop antibiotic recommendations in response to microbiologic testing results.
2. Describe clinical scenarios compelling for empiric coverage of resistant bacteria.
3. Discriminate clinical scenarios requiring initiation of antibiotics.
4. Choose appropriate risk factor–based empiric antibiotic regimens for acute infections.
5. Recognize clinical scenarios necessitating avoidance of specific antibiotics based on side effect profiles.
6. Identify clinical situations appropriate for newly approved antimicrobials.

Considerations for Successful Empiric Therapy

• Spectrum of activity for commonly used antibiotics
• Normal flora for infectious sites
• Resistance associated with common bacteria
• Pharmacodynamic influences on antibiotic dosing

Interpretation of Microbiologic Test Results 

• Gram stain results
• Culture and sensitivity results
• Minimum inhibitory concentration (MIC) evaluation
• PCR results

Antibacterial Resistance

• Trends
• Mechanisms of resistance
• Contributing factors
• Antibiotic stewardship concepts

Antibiotic Related Allergies– Penicillin and ‘Sulfa’

• Define true allergy versus side effect
• Penicillin allergy and cephalosporin cross sensitivity 
• ‘Sulfa’ allergy

SARS-CoV-2

• Clinical trial data for therapeutics
• Clinical trial data for vaccines

Skin and Soft Tissue Infections

• Streptococcus pyogenes vs. MRSA
• Evidence for antibiotic management
• IDSA treatment guidelines
• Vancomycin AUC/MIC monitoring

Pneumonia

• Evidence for pathogen etiology
• Evidence for antibiotic management
• IDSA/ATS community-acquired pneumonia treatment guidelines
• Resistance risk factors and management
• IDSA/ATS hospital- and ventilator-acquired pneumonia treatment guidelines
• New antibiotics for MDR infections

Influenza

• Evidence on vaccine timing and use in older adults
• Clinical trial data for therapeutics
• IDSA/CDC treatment guidelines

Urinary Tract Infections

• Resistance trends
• Clinical trial data for therapeutics
• Antibiotics for MDR infections

Clostridium Difficile Infection

• Risk factor literature review
• Compare antibiotic risk levels
• IDSA treatment guidelines
• Clinical trial data for therapeutics
• Probiotics prophylaxis evidence review